St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist

Psychosomatics

Volumn 44, Issue 4, 2003, Pages 271-282

  Hammerness, Paul ^b   Basch, Ethan ^b   Ulbricht, Catherine ^a   Barrette, E P ^b   Foppa, Ivo ^b   Basch, Samuel ^b   Bent, Steve ^b   Boon, Heather ^b   Ernst, Edzard ^b  

^a Natural Standard   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; DESOGESTREL; DRUG METABOLITE; ETHINYLESTRADIOL; FLUOXETINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; IRINOTECAN; MIDAZOLAM; NEFAZODONE; NEVIRAPINE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERTRALINE; SIMVASTATIN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

AGITATION; ALLERGY; ALOPECIA; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONSULTATION; DELIRIUM; DEPRESSION; DIAPHORESIS; DIARRHEA; DISORIENTATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DYSPEPSIA; DYSPNEA; ERECTILE DYSFUNCTION; EUROPE; EVIDENCE BASED MEDICINE; FATIGUE; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERICUM PERFORATUM; HYPERREFLEXIA; HYPERTENSION; HYPOMANIA; INSOMNIA; INVOLUNTARY MOVEMENT; IRRITABILITY; LIBIDO DISORDER; MANIA; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; ORGASM DISORDER; PHARMACODYNAMICS; PHOTOTOXICITY; PREGNANCY; PRURITUS; PSYCHIATRIST; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SPERMATOZOON MOTILITY; TACHYCARDIA; THROMBOEMBOLISM; TREMOR; UROGENITAL TRACT DISEASE; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0037529437     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.44.4.271     Document Type: Review

References (129)

1. Bombardelli E, Morazzoni P: Hypericum perforatum. Fitoterapia 1995; 66:43-68
2. Nahrstedt A, Butterweck V: Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30(suppl 2):129-134
3. Butterweck V, Wall A, Lieflander-Wulf U, Winterhoff H, Nahrstedt A: Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 1997; 30(suppl 2):117-124
4. Müller WE, Rolli M, Schafer C, Hafner U: Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30(suppl 2):102-107
5. Bhattacharya SK, Chakrabarti A, Chatterjee SS: Activity profiles of two hyperforin-containing Hypericum extracts in behavioral models. Pharmacopsychiatry 1998; 31(suppl 1):22-29
6. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, De Sarro G, Caputi A: Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry 2001; 34:45-49
7. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E: Effect of acute administration of Hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry 2000; 33:14-18
8. Cott JM: In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30(suppl 2):108-112
9. Chatterjee SS, Bhattacharya SK, Singer A, Wonnemann M, Mueller WE: Hyperforin inhibits synaptosomal uptake of neurotransmitters in vitro and shows antidepressant activity in vivo. Pharmazie 1998; 53:9
10. Wonnemann M, Singer A, Muller WE: Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000; 23:188-197
11. Nathan PJ: Hypericum perforatum (St John's wort): a non-selective reuptake inhibitor? a review of the recent advances in its pharmacology. J Psychopharmacol 2001; 15:47-54
12. Yu PH: Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 2000; 33:60-65
13. Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB: Neuropharmacology of St John's wort (Hypericum). Ann Pharmacother 1998; 32:1201-1208
14. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H: Inhibition of monoamine oxidase by hypericin. Planta Med 1984; 50:272-274
15. Demisch L, Holzl J, Gollnik B, Kaczmarczyk P: Identification of selective MAO-type-A inhibitors in Hypericum perforatum L. Pharmacopsychiatry 1989; 22:194
16. Thiede HM, Walper A: Inhibition of MAO and COMT by Hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S54-S56
17. Bladt S, Wagner H: Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S57-S59
18. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I: Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S47-S53
19. Neary JT, Bu Y: Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 1999; 816:358-363
20. Teufel-Mayer R, Gleitz J: Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 1997; 30(suppl 2):113-116
21. Raffa RB: Screen of receptor and uptake-site activity of hypericin component of St John's wort reveals sigma receptor binding. Life Sci 1998; 62:L265-L270
22. Thiele B, Brink I, Ploch M: Modulation of cytokine expression by Hypericum extract. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S60-S62
23. Schule C, Baghai T, Ferrera A, Laakmann G: Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 2001; 34(suppl 1):S127-S133
24. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I: Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40:2087-2093
25. Stock S, Holzi J: Pharmacokinetics test of [14C]labeled pseudo-hypericin from Hypericin perforatum and kinetics of hypericin in man. Planta Med 1991; 57:A61-A62
26. Cott JM: Herb-drug interactions. CNS Spectrums 2001; 6:827-832
27. Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: St John's wort: a hidden risk for transplant patients. Prog Transplant 2001; 11:116-120
28. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP 3A4. Clin Pharmacol Ther 2000; 68:598-604
29. Martinez B, Kasper S, Ruhrmann S, Moller HJ: Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S29-S33
30. Kasper S: Treatment of seasonal affective disorder (SAD) with Hypericum extract. Pharmacopsychiatry 1997; 30(suppl 2):89-93
31. Wheatley D: Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999; 15:33-37
32. Panijel M: [Treatment of moderately severe anxiety states]. Therapiewoche 1985; 35:4659-4668 (German)
33. Taylor LH, Kobak KA: An open-label trial of St John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000; 61:575-578
34. Leuschner G: Preclinical toxicology profile of Hypericum extract LI 160. Phytomedicine Suppl 1996; 1:104
35. Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG: [Genotoxicity of a standardized Hypericum extract]. Arzneimittelforschung 1990; 40:851-855 (German)
36. Greeson JM, Sanford B, Monti DA: St John's wort: a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001; 153:402-414
37. Poginsky B, Westendorf J, Prosenc N, Kuppe M, Marquardt H: Johanniskraut (Hypericum perforatum L): Genotoxizität bedingt durch den Quercetingehalt. Dtsch Apoth Ztg 1988; 128:13641366
38. Schimmer O, Hafele F, Kruger A: The mutagenic potencies of plant extracts containing quercetin in Salmonella typhimurium TA98 and TA100. Mutat Res 1988; 206:201-208
39. Grush LR, Nierenberg A, Keefe B, Cohen LS: St John's wort during pregnancy (letter). JAMA 1998; 280:1566
40. Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD: Effect of prenatally administered Hypericum (St John's wort) on growth and physical maturation of mouse offspring. Am J Obstet Gynecol 2001; 184:191-195
41. Klier CM, Schafer MR, Schmid-Siegel B, Lenz G, Mannel M: St John's wort (Hypericum perforatum) - is it safe during breast-feeding? Pharmacopsychiatry 2002; 35:29-30
42. Woelk H, Burkard G, Grunwald J: Benefits and risks of the Hypericum extract LI 160: drug-monitoring study with 3,250 patients. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S34-S38
43. Schakau D, Hiller K-O, Schultz-Zehden W, Teschner F: Risk/benefit profile of St John's wort extract: STEI 300 in 2,404 patients with various degrees of psychiatric disturbance. Psychopharmakotherapie 1996; 3:116-122
44. Ernst E, Rand JI, Barnes J, Stevinson C: Adverse effects profile of the herbal antidepressant St John's wort (Hypericum perforatum L). Eur J Clin Pharmacol 1998; 54:589-594
45. Schulz V: Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001; 8:152-160
46. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D: St John's wort for depression - an overview and meta-analysis of randomized clinical trials. Br Med J 1996; 313:253-258
47. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U: Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978-1986
48. Kim HL, Streltzer J, Goebert D: St John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187:532-539
49. Gaster B, Holroyd J: St John's wort for depression: a systematic review. Arch Intern Med 2000; 160:152-156
50. Vorbach EU, Arnoldt KH, Hubner WD: Efficacy and tolerability of St John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997; 30(suppl 2):81-85
51. Schrader E: Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15:61-68
52. Linde K, Mulrow CD: St John's wort for depression. Cochrane Database Syst Rev 2000; 2: CD000448
53. Biber A, Fischer H, Romer A, Chatterjee SS: Oral bioavailability of hyperforin from Hypeficum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31(suppl 1):36-43
54. Araya OS, Ford EJ: An investigation of the type of photosensitization caused by the ingestion of St John's wort by calves. J Comp Pathol 1981; 91:135-141
55. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J: [Reversible increase in photosensitivity to UV-B caused by St John's wort extract]. Hautarzt 1997; 48:249-252 (German)
56. Holme SA, Roberts DL: Erythroderma associated with St John's wort. Br J Dermatol 2000; 143:1127-1128
57. Lane-Brown MM: Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum) (letter). Med J Aust 2000; 172:302
58. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT: Phase I studies of hypericin, the active compound in St John's wort, as an antiretroviral agent in HIV-infected adults: AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130:510-514
59. Jacobson JM, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, Cabana BE, Lee D, Spritzler J, Prince AM: Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001; 45:517-524
60. Brockmöller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I: Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30(suppl 2):94-101
61. Schempp CM, Muller K, Winghofer B, Schulte-Monting J, Simon JC: Single-dose and steady-state administration of Hypericum perforatum extract (St John's wort) extract does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation (letter). Arch Dermatol 2001; 137:512-513; correction, 137:1380
62. Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC: Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria (letter). Lancet 1999; 353:2129
63. Bernd A, Ramirez-Bosca A, Kippenberger S, Diaz Alperi J, Miquel J, Villalba Garcia JF, Pamies Mira D, Kaufmann R: Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochem Photobiol 1999; 2:218-221
64. Parker V, Wong AH, Boon HS, Seeman MV: Adverse reactions to St John's wort. Can J Psychiatry 2001; 46:77-79
65. Bove GM: Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 1998; 352:1121-1122
66. Woelk H, Burkard G, Grunwald J: Nutzen und Risikobewertung des Hypericum-extraktes LI 160 auf der Basis einer Drug-Monitoring-Studie mit 3250 patienten. Nervenheilkunde 1993; 12:308-313
67. Schneck C: St John's wort and hypomania (letter). J Clin Psychiatry 1998; 59:689
68. Nierenberg AA, Burt T, Matthews J, Weiss AP: Mania associated with St John's wort. Biol Psychiatry 1999; 46:1707-1708
69. Moses EL, Mallinger AG: St John's wort: three cases of possible mania induction. J Clin Psychopharmacol 2000; 20:115-117
70. Guzelcan Y, Scholte WF, Assies J, Becker HE: [Mania during the use of a combination preparation with St John's wort]. Ned Tijdschr Geneeskd 2001; 145:1943-1945 (Dutch)
71. Fahmi M: A case of mania induced by hypericum. World J Biol Psychiatry 2002; 3:58-59
72. Spinella M: Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16:359-367
73. Barbenel DM, Yusufi B, O'Shea D, Bench CJ: Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. J Psychopharmacol 2000; 14:84-86
74. Brown TM: Acute St John's wort toxicity. Am J Emerg Med 2000; 18:231-232
75. Beckman SE, Sommi RW, Switzer J: Consumer use of St John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000; 20:568-574
76. Lal S, Iskandar H: St John's wort and schizophrenia. Can Med Assoc J 2000; 163:262-263
77. Laird RD, Webb M: Psychotic episode during use of St John's wort. J Herbal Pharmacotherapy 2001; 1:81-87
78. Patel S: Hypertensive crisis associated with St. John's wort. Am J Med 2002; 112:507-508
79. Czekalla J, Gastpar M, Hubner WD, Jager D: The effect of Hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 1997; 30(suppl 2):86-88
80. Schrader E, Meier B, Brattstrom A: Hypericum treatment of mild-moderate depression in a placebo-controlled study: a prospective, double blind, randomized, placebo-controlled, multicenter study. Hum Psychopharmacol 1998; 13:163-169
81. Hypericum Depression Trial Study Group: Effect of Hypericum perforatum in major depressive disorder: a randomized controlled trial. JAMA 2002; 287:1807-1814
82. Bhopal JS: St John's wort-induced sexual dysfunction. Can J Psychiatry 2001; 46:456-457
83. Assalian P: Sildenafil for St John wort-induced sexual dysfunction. J Sex Marital Ther 2000; 26:357-358
84. Ondrizek RR, Chan PJ, Patton WC, King A: Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet 1999; 16:87-91
85. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH: St John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-457
86. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA: St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97:7500-7502
87. Budzinski JW, Foster BC, Vandenhoek S, Amason JT: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7:273-282
88. Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294:88-95
89. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC: Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66:L133-L139
90. Bray BJ, Perry NB, Menkes DB, Rosengren RJ: St John's wort extract induces CYP3A and CYP2E1 in the Swiss webster mouse. Toxicol Sci 2002; 66:27-33
91. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W: Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68:605-612
92. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J: Profound drop of cyclosporin A whole blood trough levels caused by St John's wort (Hypericum perforatum) (letter). Transplantation 2000; 69:2229-2230
93. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J: Drug interaction of St John's wort with cyclosporin (letter). Lancet 2000; 355:1912
94. Mai I, Kruger H, Budde K, Johne A, Brockmoller J, Neumayer HH, Roots I: Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38:500-502
95. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR: Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001; 71:239-241
96. Moschella C, Jaber BL: Interaction between cyclosporine and Hypericum perforatum after organ transplantation. Am J Kidney Dis 2001; 38:1105-1107
97. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort (letter). Lancet 2000; 355:548-549
98. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE: Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33:853-855
99. Ahmed SM, Banner NR, Dubrey SW: Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients (letter). J Heart Lung Transplant 2001; 20:795
100. Yue QY, Bergquist C, Gerden B: Safety of St John's wort. Lancet 2000; 355:576-577
101. Ratz AE, von Moos M, Drewe J: [St John's wort: a pharmaceutical with potentially dangerous interactions]. Schweiz Rundsch Med Prax 2001; 90:843-849 (German)
102. Schwarz UI: Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55:112-113
103. Hindmarch M: Interactions of the oral contraceptive pill with antibiotics and St John's wort: knowledge of female college students. Fam Pract 2002; 19:708
104. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A: Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70:518-524
105. Smith M, Lin KM, Zheng YP: PIII-89 an open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng or ginkgo biloba. Clin Pharmacol Ther 2001; 69:P86
106. de Maat MM, Hoetelmans RM, Mathot RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH: Drug interaction between St John's wort and nevirapine. AIDS 2001; 15:420-421
107. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J: Indinavir concentrations and St John's wort (letter). Lancet 2000; 355:547-548; correction, 2001; 357:1210
108. Mathijssen RHJ, Verweij J, De Bruijn P, De Jonge MJA, Sparreboom A: Modulation of irinotecan (CPT-11) metabolism by St John's wort in cancer patients, in 2002 Proceedings of the American Association for Cancer Research. Philadelphia, AACR, 2002, abstract 2443
109. Nebel A, Schneider BJ, Baker RK, Kroll DJ: Potential metabolic interaction between St John's wort and theophylline (letter). Ann Pharmacother 1999; 33:502
110. Roots I, Johne A, Schmider J, Brockmöller J, Maurer A, Störmer E, Donath F: Interaction of a herbal extract from St John's wort with amitriptyline and its metabolites (abstract). Clin Pharmacol Ther 2000; 67:159
111. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I: Decreased plasma levels of amitriptyline and its metabolites on co-medication with an extract from St John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22:46-54
112. Sadock BJ, Sadock VA (eds): Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th ed. Baltimore, Lippincott Williams & Wilkins, 2000
113. Waksman JC, Hard K, Jolliff H, et al: Serotonin syndrome associated with the use of St John's wort and paroxetine (abstract). J Toxicol Clin Toxicol 2000; 38:521
114. Lantz MS, Buchalter E, Giambanco V: St John's wort and anti-depressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12:7-10
115. Gordon JB: SSRIs and St John's wort: possible toxicity? (letter). Am Fam Physician 1998; 57:950, 953
116. Schmidt U, Harrer U, Kuhn W, Berger-Deinert W, Luther D: Interaction of Hypericum extract with alcohol: placebo-controlled study with 32 volunteers. Nervenheilkunde 1993; 12:314-319
117. Koupparis LS: Harmless herbs: a cause for concern? Anaesthesia 2000; 55:101-102
118. Irefin S, Sprung J: A possible cause of cardiovascular collapse during anesthesia: long-term use of St John's wort. J Clin Anesth 2000; 12:498-499
119. Crowe S: Delayed emergence and St John's wort. Anesthesiology 2002; 96:1025-1027
120. Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ: Catalytic inhibition of human DNA topoisomerase II alpha by hypericin, a naphthodianthrone from St John's wort (Hypericum perforatum). Biochem Pharmacol 2001; 62:1059-1070
121. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338-345
122. Khawaja IS, Marotta RF, Lippmann S: Herbal medicines as a factor in delirium. Psychiatr Serv 1999; 50:969-970
123. Miller LG: Drug interactions known or potentially associated with St John's wort. J Herbal Pharmacother 2001; 1:51-64
124. Ladner DP, Klein SD, Steiner RA, Walt H: Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and Hypericum extract, an herbal antidepressant (letter). Br J Dermatol 2001; 144:916-918
125. Ferko N, Levine MA: Evaluation of the association between St John's wort and elevated thyroid-stimulating hormone. Pharmacotherapy 2001; 21:1574-1578
126. Cott J: NCDEU update: natural product formulations available in Europe for psychotropic indications. Psychopharmacol Bull 1995; 31:745-751
127. Miller AL: St John's wort (Hypericum perforatum): clinical effects on depression and other conditions. Altern Med Rev 1998; 3:18-26
128. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280:1569-1575
129. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB: Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001; 135:344-351